Cargando…

Prescribing Variation in General Practices in England Following a Direct Healthcare Professional Communication on Mirabegron

Introduction: Pharmacovigilance may detect safety issues after marketing of medications, and this can result in regulatory action such as direct healthcare professional communications (DHPC). DHPC can be effective in changing prescribing behaviour, however the extent to which prescribers vary in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Moriarty, Frank, Razzaque, Shegufta, McDowell, Ronald, Fahey, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210595/
https://www.ncbi.nlm.nih.gov/pubmed/30282903
http://dx.doi.org/10.3390/jcm7100320
_version_ 1783367151640379392
author Moriarty, Frank
Razzaque, Shegufta
McDowell, Ronald
Fahey, Tom
author_facet Moriarty, Frank
Razzaque, Shegufta
McDowell, Ronald
Fahey, Tom
author_sort Moriarty, Frank
collection PubMed
description Introduction: Pharmacovigilance may detect safety issues after marketing of medications, and this can result in regulatory action such as direct healthcare professional communications (DHPC). DHPC can be effective in changing prescribing behaviour, however the extent to which prescribers vary in their response to DHPC is unknown. This study aims to explore changes in prescribing and prescribing variation among general practitioner (GP) practices following a DHPC on the safety of mirabegron, a medication to treat overactive bladder (OAB). Methods: This is an interrupted time series study of English GP practices from 2014–2017. National Health Service (NHS) Digital provided monthly statistics on aggregate practice-level prescribing and practice characteristics (practice staff and registered patient profiles, Quality and Outcomes Framework indicators, and deprivation of the practice area). The primary outcome was monthly mirabegron prescriptions as a percentage of all OAB drug prescriptions and we assessed the change following a DHPC issued by the European Medicines Agency in September 2015. The DHPC stated mirabegron use was contraindicated with severe uncontrolled hypertension and cautioned with hypertension. Variation between practices in mirabegron prescribing before and after the DHPC was assessed using the systematic component of variation (SCV). Multilevel segmented regression with random effects quantified the change in level and trend of prescribing after the DHPC. Practice characteristics were assessed for their association with a reduction in prescribing following the DHPC. Results: This study included 7408 practices. During September 2015, 88.9% of practices prescribed mirabegron and mirabegron comprised a mean of 8.2% (SD 6.8) of OAB prescriptions. Variation between practices was classified as very high and the median SCV did not change significantly (p = 0.11) in the six months after the September 2015 DHPC (12.4) compared to before (11.6). Before the DHPC, the share of mirabegron over all OAB drug prescriptions increased by 0.294 (95% confidence interval (CI), 0.287, 0.301) percentage points per month. There was no significant change in the month immediately after the DHPC (−0.023, 95% CI −0.105 to 0.058), however there was a significant reduction in trend (−0.036, 95% CI −0.049 to −0.023). Higher numbers of registered patients, patients aged ≥65 years, and practice area deprivation were associated with having a significant decrease in level and slope of mirabegron prescribing post-DHPC. Conclusion: Variation in mirabegron prescribing was high over the study period and did not change substantively following the DHPC. There was no immediate prescribing change post-DHPC, although the monthly growth did slow. Knowledge of the degree of variation in and determinants of response to safety communications may allow those that do not change prescribing habits to be provided with additional support.
format Online
Article
Text
id pubmed-6210595
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62105952018-11-02 Prescribing Variation in General Practices in England Following a Direct Healthcare Professional Communication on Mirabegron Moriarty, Frank Razzaque, Shegufta McDowell, Ronald Fahey, Tom J Clin Med Article Introduction: Pharmacovigilance may detect safety issues after marketing of medications, and this can result in regulatory action such as direct healthcare professional communications (DHPC). DHPC can be effective in changing prescribing behaviour, however the extent to which prescribers vary in their response to DHPC is unknown. This study aims to explore changes in prescribing and prescribing variation among general practitioner (GP) practices following a DHPC on the safety of mirabegron, a medication to treat overactive bladder (OAB). Methods: This is an interrupted time series study of English GP practices from 2014–2017. National Health Service (NHS) Digital provided monthly statistics on aggregate practice-level prescribing and practice characteristics (practice staff and registered patient profiles, Quality and Outcomes Framework indicators, and deprivation of the practice area). The primary outcome was monthly mirabegron prescriptions as a percentage of all OAB drug prescriptions and we assessed the change following a DHPC issued by the European Medicines Agency in September 2015. The DHPC stated mirabegron use was contraindicated with severe uncontrolled hypertension and cautioned with hypertension. Variation between practices in mirabegron prescribing before and after the DHPC was assessed using the systematic component of variation (SCV). Multilevel segmented regression with random effects quantified the change in level and trend of prescribing after the DHPC. Practice characteristics were assessed for their association with a reduction in prescribing following the DHPC. Results: This study included 7408 practices. During September 2015, 88.9% of practices prescribed mirabegron and mirabegron comprised a mean of 8.2% (SD 6.8) of OAB prescriptions. Variation between practices was classified as very high and the median SCV did not change significantly (p = 0.11) in the six months after the September 2015 DHPC (12.4) compared to before (11.6). Before the DHPC, the share of mirabegron over all OAB drug prescriptions increased by 0.294 (95% confidence interval (CI), 0.287, 0.301) percentage points per month. There was no significant change in the month immediately after the DHPC (−0.023, 95% CI −0.105 to 0.058), however there was a significant reduction in trend (−0.036, 95% CI −0.049 to −0.023). Higher numbers of registered patients, patients aged ≥65 years, and practice area deprivation were associated with having a significant decrease in level and slope of mirabegron prescribing post-DHPC. Conclusion: Variation in mirabegron prescribing was high over the study period and did not change substantively following the DHPC. There was no immediate prescribing change post-DHPC, although the monthly growth did slow. Knowledge of the degree of variation in and determinants of response to safety communications may allow those that do not change prescribing habits to be provided with additional support. MDPI 2018-10-03 /pmc/articles/PMC6210595/ /pubmed/30282903 http://dx.doi.org/10.3390/jcm7100320 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Moriarty, Frank
Razzaque, Shegufta
McDowell, Ronald
Fahey, Tom
Prescribing Variation in General Practices in England Following a Direct Healthcare Professional Communication on Mirabegron
title Prescribing Variation in General Practices in England Following a Direct Healthcare Professional Communication on Mirabegron
title_full Prescribing Variation in General Practices in England Following a Direct Healthcare Professional Communication on Mirabegron
title_fullStr Prescribing Variation in General Practices in England Following a Direct Healthcare Professional Communication on Mirabegron
title_full_unstemmed Prescribing Variation in General Practices in England Following a Direct Healthcare Professional Communication on Mirabegron
title_short Prescribing Variation in General Practices in England Following a Direct Healthcare Professional Communication on Mirabegron
title_sort prescribing variation in general practices in england following a direct healthcare professional communication on mirabegron
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210595/
https://www.ncbi.nlm.nih.gov/pubmed/30282903
http://dx.doi.org/10.3390/jcm7100320
work_keys_str_mv AT moriartyfrank prescribingvariationingeneralpracticesinenglandfollowingadirecthealthcareprofessionalcommunicationonmirabegron
AT razzaqueshegufta prescribingvariationingeneralpracticesinenglandfollowingadirecthealthcareprofessionalcommunicationonmirabegron
AT mcdowellronald prescribingvariationingeneralpracticesinenglandfollowingadirecthealthcareprofessionalcommunicationonmirabegron
AT faheytom prescribingvariationingeneralpracticesinenglandfollowingadirecthealthcareprofessionalcommunicationonmirabegron